These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 15679174)

  • 1. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data.
    Shou M
    Curr Opin Drug Discov Devel; 2005 Jan; 8(1):66-77. PubMed ID: 15679174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants.
    Bachmann KA; Lewis JD
    Ann Pharmacother; 2005 Jun; 39(6):1064-72. PubMed ID: 15886285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
    Ito K; Sugiyama Y
    Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.
    De Buck SS; Mackie CE
    Expert Opin Drug Metab Toxicol; 2007 Dec; 3(6):865-78. PubMed ID: 18028030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances.
    Obach RS
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):81-9. PubMed ID: 19152216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of mechanism-based CYP inhibition for predicting drug-drug interactions.
    Zhou ZW; Zhou SF
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):579-605. PubMed ID: 19466877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
    Grime KH; Bird J; Ferguson D; Riley RJ
    Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transporter-mediated drug--drug interactions involving OATP substrates: predictions based on in vitro inhibition studies.
    Yoshida K; Maeda K; Sugiyama Y
    Clin Pharmacol Ther; 2012 Jun; 91(6):1053-64. PubMed ID: 22534868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data.
    Lu C; Miwa GT; Prakash SR; Gan LS; Balani SK
    Drug Metab Dispos; 2007 Jan; 35(1):79-85. PubMed ID: 17020957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
    Guest EJ; Aarons L; Houston JB; Rostami-Hodjegan A; Galetin A
    Drug Metab Dispos; 2011 Feb; 39(2):170-3. PubMed ID: 21036951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data.
    Yao C; Levy RH
    J Pharm Sci; 2002 Sep; 91(9):1923-35. PubMed ID: 12210040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry.
    Soars MG; Webborn PJ; Riley RJ
    Mol Pharm; 2009; 6(6):1662-77. PubMed ID: 19402709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confidence assessment of the Simcyp time-based approach and a static mathematical model in predicting clinical drug-drug interactions for mechanism-based CYP3A inhibitors.
    Wang YH
    Drug Metab Dispos; 2010 Jul; 38(7):1094-104. PubMed ID: 20368327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of human pharmacokinetics - renal metabolic and excretion clearance.
    Fagerholm U
    J Pharm Pharmacol; 2007 Nov; 59(11):1463-71. PubMed ID: 17976256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics.
    Iwatsubo T; Hirota N; Ooie T; Suzuki H; Sugiyama Y
    Biopharm Drug Dispos; 1996 May; 17(4):273-310. PubMed ID: 8845471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Advances and related issues in the use of in vitro methods to predict metabolic clearance rate of new drugs].
    Zhang Q; Wang GJ
    Yao Xue Xue Bao; 2007 Oct; 42(10):1023-8. PubMed ID: 18229605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.
    Lutz JD; Isoherranen N
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):449-66. PubMed ID: 22384784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
    Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
    J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.